New psoriasis shot shows promise in Mid-Stage trial
Disease control
Recruiting now
This study tests a new medicine called HB0017, given as an injection, for people with moderate to severe plaque psoriasis. The goal is to see how well different dosing schedules clear the skin and reduce symptoms. About 200 adults aged 18-75 with chronic psoriasis will participat…
Phase: PHASE2 • Sponsor: Huabo Biopharm Co., Ltd. • Aim: Disease control
Last updated May 02, 2026 18:03 UTC